King Minos II hall
Hereditary nephropathies
N.1A. Polycystic kidney disease
1. Safety and effectiveness of Tolvaptan
2. New KDIGO Guidelines
3. Genetic tests: what should I know?
N.2A. Other hereditary nephropathies
1. Fabry Disease: what should I know?
2. Type-4 collagen gene mutation related nephropathies
3. Hereditary tubulointerstitial nephropathies
Cardiovascular morbidity
Coffee break
N.3A. Cardiovascular morbidity in CKD
1. Treatment on hyperlipidaemia: what's new?
2. HIF inhibitors: their place in clinical practice
3. Update in the management of hyperkalaemia
Clinical Nephrology
Coffee break
N.4A. IgA nephropathy
1. The role of B cells and BAFF/APRIL
2. New and emerging therapies in IgA nephropathy
3. How should I manage the patient with IgA nephropathy
Lunch
General assembly
Hypertension
N.5A. Hypertension
1. Management of hypertension in patients with CKD
2. Resistant hypertension
3. Use of diuretics in CKD: benefits and risks
4. Hypertension in dialysis
Breakthrough in Nephrology
Coffee break
N.6A. Changing the status quo in CKD
1. SGLT2 inhibitors: what's new?
2. The place of GLP-1 agonists in clinical practice
3. The place of MRAs in clinical practice
Obesity: chronic disease and axeses
State of the art lecture
Coffee break
Haemodialysis
N.7A. Haemodialysis
1. Uremic pruritus: systematic review, evaluation and management
2. Response to ultrafiltration in dialysis
3. Management of the patient with diabetes on dialysis
Close
scan me
Approved by:
Participants:
Participants:
